Controversial DNA sequencing company 23andMe announced the first of 10 deals to be signed with large biotech and pharma firms on Tuesday January 6. Their $60 million partnership with Genentech
23andMe
About Us
Evolution Bioscience is a global consultancy firm, specialising in market intelligence, strategy formulation, technology transfer and commercialisation services, covering the full range of Biotechnology sectors.Recent Posts
2016 © Evolution Bioscience / Darwin Hutton Partners